Table 4.

Microvascular function data.

Flow (Perfusion Units, in mV)							P
	Treatment group
	Clopidogrel (n = 20)		Prasugrel (n = 15)		Ticagrelor (n = 21)
	Median	IQR	Median	IQR	Median	IQR
Screening	44	28–74	39	27–68	61	20–135
Resting							0.440
Peak during Hyperemia	119	71–173	108	64–146	124	84–197	0.363
% PORH	156	65–229	146	86–224	88	40–265	0.502
After oral loading	45	29–83	29	19–48	50	19–116
Resting							0.158
Peak during Hyperemia	111	75–160	112	64–148	133	73–198	0.572
% PORH	140*	70–180	216*	159–457	159*	58–342	0.022**
1 day after stenting	59	40–80	31	23–52	40	25–82
Resting							0.091
Peak during Hyperemia	138	89–179	102	66–136	92	84–172	0.437
% PORH	101	47–177	110†	82–303	139	95–264	0.287
1 week after stenting	30	17–60	49	20–75	33	21–75
Resting							0.490
Peak during Hyperemia	94	81–135	116	88–192	120	67–173	0.599
% PORH	193	113–327	135	86–298	224	90–352	0.726
1 Month after stenting	49	27–81	57	30–71	57	26–95
Resting							0.609
Peak during Hyperemia	119	96–140	119	91–130	134	9–175	0.436
% PORH	152	46–233	106	100–184	125	65–175	0.894

^*: P = 0.015 among groups for the change in %PORH between screening and following oral loading (P = 0.007 for the comparison clopidogrel vs. prasugrel; P = 0.329 for the comparison prasugrel vs. ticagrelor and P = 0.042 for the comparison clopidogrel vs. ticagrelor);

^**: P = 0.003 for the comparison prasugrel vs. clopidogrel, P = 0.117 for the comparison prasugrel vs. ticagrelor, P = 0.415 for the comparison clopidogrel vs. ticagrelor;

^† = 0.026 for the comparison with immediately after loading.